Registered title, quoted from ClinicalTrials.gov
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07309276, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Have received any investigational drug within 4 weeks or 5 half-lives before the first use of the study drug;
Exclusion criterion 19
Have received local small-scale radiotherapy within 14 days;
Exclusion criterion 22
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Inclusion criterion 5
According to the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), there must be at least one measurable lesion.
Inclusion criterion 4
Tumor histological or cytological pathological confirmation of combined large cell neuroendocrine carcinoma or sarcomatoid lesion, or NSCLC with small cell lung cancer component;
Exclusion criterion 2
Participants who were diagnosed with any other malignant tumor within 5 years.
Exclusion criterion 26
Female participants with reproductive capacity (WOCBP) who have sexual life with an unsterilized male partner and who have signed the informed consent must have a negative serum pregnancy test result within 7 days before the first administration, and must agree to take effective contraceptive measures from the time of signing the ICF until 7 months after the last administration of the study.
Inclusion criterion 8
Unsterilized male participants who have sexual life with a fertile female partner must agree to use the effective contraceptive measures after signing the ICF until 4 months after the last administration of the study. During this period, sperm donation is prohibited.
Inclusion criterion 9
Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
Exclusion criterion 27
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07309276, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- The age between 18 and 75 years old, and any gender.
- Local advanced, metastatic or recurrent NSCLC.
- ES-SCLC.
- According to the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), there must be at least one measurable lesion.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Expected survival period of ≥ 12 weeks.
- The functions of important organs meet the requirements.
- Female participants with reproductive capacity (WOCBP) who have sexual life with an unsterilized male partner and who have signed the informed consent must have a negative serum pregnancy test result within 7 days before the first administration, and must agree to take effective contraceptive measures from the time of signing the ICF until 7 months after the last administration of the study.
- Unsterilized male participants who have sexual life with a fertile female partner must agree to use the effective contraceptive measures after signing the ICF until 4 months after the last administration of the study. During this period, sperm donation is prohibited.
- The participants voluntarily participate in this study and sign the informed consent.
Exclusion Criteria:
- Accompanying the following disease states:
- Tumor histological or cytological pathological confirmation of combined large cell neuroendocrine carcinoma or sarcomatoid lesion, or NSCLC with small cell lung cancer component;
- NSCLC patients with positive driver mutations;
- Patients with known meningeal metastasis;
- Patients with symptomatic brain metastases;
- Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites;
- Unatable spinal cord compression;
- Participants in Cohort 1 and Cohort 4 need to exclude any of the following conditions:
- Within one month before the first use of the study drug, any clinically significant hemoptysis or tumor bleeding;
- High bleeding risk; tumor invading important organs, high risks of perforation, esophageal-tracheal fistula, massive hemoptysis, etc.;
- Obvious bleeding tendency or severe coagulation dysfunction history, etc;
- Recent gastrointestinal perforation, gastrointestinal obstruction, trachea-esophageal fistula, abdominal fistula or intra-abdominal abscess, or currently having high-risk factors for hollow organ perforation/ fistula formation, or active inflammatory bowel disease, etc;
- Presence of severe, non-healed or open wounds, active ulcers or untreated fractures;
- Have poorly controlled hypertension;
- Have used antiplatelet drugs or anticoagulant therapy within 14 days;
- Have experienced a drug-related adverse event that led to permanent discontinuation of the medication during previous Bevacizumab and similar agent treatments;
- Have received any of the following treatments:
- Immune-mediated treatments (only for part Two);
- Have received any investigational drug within 4 weeks or 5 half-lives before the first use of the study drug;
- Have been enrolled in another clinical study;
- Have undergone major surgery within 4 weeks;
- Have received local small-scale radiotherapy within 14 days;
4.Have not recovered to ≤ CTCAE grade 1 toxicity or the level specified in the inclusion/exclusion criteria.
5.Have known allergies to any study treatment or its excipients or have experienced an allergic reaction.
6.Have experienced a drug-related AE that led to permanent discontinuation of the anti-PD-(L)1 antibody treatment.
7.Have any of the following cardiac examination results:
- Long QT;
- Left ventricular ejection fraction (LVEF) < 50%;
8.Have a history of diagnosed or suspected ILD, drug-induced pneumonia, or other severe lung diseases.
9.Have experienced a severe infection within 4 weeks.
10.Have a history of immunodeficiency, or have a history of organ transplantation and allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation.
11.Have active pulmonary tuberculosis infection.
12.Have active hepatitis.
- Uncontrolled concurrent diseases.
- Participants who were diagnosed with any other malignant tumor within 5 years.
- Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
- Other conditions for trial participation were not considered appropriate by the investigator.
Quoted from ClinicalTrials.gov, NCT07309276, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07309276, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.